189 related articles for article (PubMed ID: 34247191)
1. HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer.
Clements ME; Holtslander L; Edwards C; Todd V; Dooyema SDR; Bullock K; Bergdorf K; Zahnow CA; Connolly RM; Johnson RW
Oncogene; 2021 Aug; 40(34):5314-5326. PubMed ID: 34247191
[TBL] [Abstract][Full Text] [Related]
2. Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism.
Dhingra K; Sahin A; Emami K; Hortobagyi GN; Estrov Z
Breast Cancer Res Treat; 1998 Mar; 48(2):165-74. PubMed ID: 9596488
[TBL] [Abstract][Full Text] [Related]
3. gp130 Cytokines Activate Novel Signaling Pathways and Alter Bone Dissemination in ER+ Breast Cancer Cells.
Omokehinde T; Jotte A; Johnson RW
J Bone Miner Res; 2022 Feb; 37(2):185-201. PubMed ID: 34477239
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitors stimulate LIFR when it is repressed by hypoxia or PTHrP in breast cancer.
Edwards CM; Clements ME; Vecchi LA; Johnson JA; Johnson RW
J Bone Oncol; 2021 Dec; 31():100407. PubMed ID: 34934614
[TBL] [Abstract][Full Text] [Related]
5. Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.
Zeng H; Qu J; Jin N; Xu J; Lin C; Chen Y; Yang X; He X; Tang S; Lan X; Yang X; Chen Z; Huang M; Ding J; Geng M
Cancer Cell; 2016 Sep; 30(3):459-473. PubMed ID: 27622335
[TBL] [Abstract][Full Text] [Related]
6. LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer.
Li M; Viswanadhapalli S; Santhamma B; Pratap UP; Luo Y; Liu J; Altwegg KA; Tang W; Liu Z; Li X; Ebrahimi B; Yan H; Zou Y; Konda S; Sareddy GR; Xu Z; Chen Y; Rao MK; Brenner AJ; Kaklamani VG; Tekmal RR; Ahmed G; Raj GV; Nickisch KJ; Nair HB; Vadlamudi RK
Commun Biol; 2021 Oct; 4(1):1235. PubMed ID: 34716410
[TBL] [Abstract][Full Text] [Related]
7. Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow.
Johnson RW; Finger EC; Olcina MM; Vilalta M; Aguilera T; Miao Y; Merkel AR; Johnson JR; Sterling JA; Wu JY; Giaccia AJ
Nat Cell Biol; 2016 Oct; 18(10):1078-1089. PubMed ID: 27642788
[TBL] [Abstract][Full Text] [Related]
8. EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.
Viswanadhapalli S; Luo Y; Sareddy GR; Santhamma B; Zhou M; Li M; Ma S; Sonavane R; Pratap UP; Altwegg KA; Li X; Chang A; Chávez-Riveros A; Dileep KV; Zhang KYJ; Pan X; Murali R; Bajda M; Raj GV; Brenner AJ; Manthati V; Rao MK; Tekmal RR; Nair HB; Nickisch KJ; Vadlamudi RK
Mol Cancer Ther; 2019 Aug; 18(8):1341-1354. PubMed ID: 31142661
[TBL] [Abstract][Full Text] [Related]
9. The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling.
Spencer N; Rodriguez Sanchez AL; Gopalam R; Subbarayalu P; Medina DM; Yang X; Ramirez P; Randolph L; Aller EJ; Santhamma B; Rao MK; Tekmal RR; Nair HB; Kost ER; Vadlamudi RK; Viswanadhapalli S
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139260
[TBL] [Abstract][Full Text] [Related]
10. Leukemia inhibitory factor (LIF), cardiotrophin-1, and oncostatin M share structural binding determinants in the immunoglobulin-like domain of LIF receptor.
Plun-Favreau H; Perret D; Diveu C; Froger J; Chevalier S; Lelièvre E; Gascan H; Chabbert M
J Biol Chem; 2003 Jul; 278(29):27169-79. PubMed ID: 12707269
[TBL] [Abstract][Full Text] [Related]
11. Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130.
Hermanns HM; Radtke S; Haan C; Schmitz-Van de Leur H; Tavernier J; Heinrich PC; Behrmann I
J Immunol; 1999 Dec; 163(12):6651-8. PubMed ID: 10586060
[TBL] [Abstract][Full Text] [Related]
12. Leukemia inhibitory factor receptor signaling negatively modulates nerve growth factor-induced neurite outgrowth in PC12 cells and sympathetic neurons.
Ng YP; He W; Ip NY
J Biol Chem; 2003 Oct; 278(40):38731-9. PubMed ID: 12871977
[TBL] [Abstract][Full Text] [Related]
13. Immunization against leukemia inhibitory factor and its receptor suppresses tumor formation of breast cancer initiating cells in BALB/c mouse.
Ghanei Z; Mehri N; Jamshidizad A; Joupari MD; Shamsara M
Sci Rep; 2020 Jul; 10(1):11465. PubMed ID: 32651426
[TBL] [Abstract][Full Text] [Related]
14. PTHrP intracrine actions divergently influence breast cancer growth through p27 and LIFR.
Edwards CM; Kane JF; Smith JA; Grant DM; Johnson JA; Diaz MAH; Vecchi LA; Bracey KM; Omokehinde TN; Fontana JR; Karno BA; Scott HT; Vogel CJ; Lowery JW; Martin TJ; Johnson RW
Breast Cancer Res; 2024 Feb; 26(1):34. PubMed ID: 38409028
[TBL] [Abstract][Full Text] [Related]
15. The upper cytokine-binding module and the Ig-like domain of the leukaemia inhibitory factor (LIF) receptor are sufficient for a functional LIF receptor complex.
Aasland D; Oppmann B; Grötzinger J; Rose-John S; Kallen KJ
J Mol Biol; 2002 Jan; 315(4):637-46. PubMed ID: 11812136
[TBL] [Abstract][Full Text] [Related]
16. Role of leukemia inhibitory factor and its receptor in mouse primordial germ cell growth.
Cheng L; Gearing DP; White LS; Compton DL; Schooley K; Donovan PJ
Development; 1994 Nov; 120(11):3145-53. PubMed ID: 7720558
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of the human leukemia inhibitory factor (LIF) receptor by mitogen-activated protein kinase and the regulation of LIF receptor function by heterologous receptor activation.
Schiemann WP; Graves LM; Baumann H; Morella KK; Gearing DP; Nielsen MD; Krebs EG; Nathanson NM
Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5361-5. PubMed ID: 7777512
[TBL] [Abstract][Full Text] [Related]
18. Novel Long Non-coding RNA lncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression.
Zhang W; Shi X; Chen R; Zhu Y; Peng S; Chang Y; Nian X; Xiao G; Fang Z; Li Y; Cao Z; Zhao L; Liu G; Sun Y; Ren S
Mol Ther; 2020 Nov; 28(11):2473-2487. PubMed ID: 32592689
[TBL] [Abstract][Full Text] [Related]
19. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation.
Mosley B; De Imus C; Friend D; Boiani N; Thoma B; Park LS; Cosman D
J Biol Chem; 1996 Dec; 271(51):32635-43. PubMed ID: 8999038
[TBL] [Abstract][Full Text] [Related]
20. Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor.
Wang Y; Robledo O; Kinzie E; Blanchard F; Richards C; Miyajima A; Baumann H
J Biol Chem; 2000 Aug; 275(33):25273-85. PubMed ID: 10854424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
